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Herlitz junctional epidermolysis bullosa (H-JEB) is an incurable,
devastating, and mostly fatal inherited skin disease for which there
is only supportive care. H-JEB is caused by loss-of-function muta-
tions in LAMA3, LAMB3, or LAMC2, leading to complete loss of
laminin 332, the major component of anchoring filaments, which
mediate epidermal-dermal adherence. LAMB3 (laminin β3) muta-
tions account for 80% of patients with H-JEB, and ∼95% of H-
JEB–associated LAMB3 mutations are nonsense mutations leading
to premature termination codons (PTCs). In this study, we evaluated
the ability of gentamicin to induce PTC readthrough in H-JEB laminin
β3-null keratinocytes transfected with expression vectors encoding
eight different LAMB3 nonsense mutations. We found that genta-
micin induced PTC readthrough in all eight nonsense mutations
tested. We next used lentiviral vectors to generate stably trans-
duced H-JEB cells with the R635X and C290X nonsense mutations.
Incubation of these cell lines with various concentrations of genta-
micin resulted in the synthesis and secretion of full-length laminin
β3 in a dose-dependent and sustained manner. Importantly, the
gentamicin-induced laminin β3 led to the restoration of laminin
332 assembly, secretion, and deposition within the dermal/epider-
mal junction, as well as proper polarization of α6β4 integrin in basal
keratinocytes, as assessed by immunoblot analysis, immunofluores-
cent microscopy, and an in vitro 3D skin equivalent model. Finally,
newly restored laminin 332 corrected the abnormal cellular pheno-
type of H-JEB cells by reversing abnormal cell morphology, poor
growth potential, poor cell-substratum adhesion, and hypermotility.
Therefore, gentamicin may offer a therapy for H-JEB and other
inherited skin diseases caused by PTC mutations.
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Herlitz junctional epidermolysis bullosa (H-JEB) is a lethalskin-fragility disorder that occurs due to loss-of-function
mutations in the LAMA3, LAMB3, or LAMC2 gene, which en-
code laminin α3, β3, or γ2, respectively (1, 2). These monomers
trimerize to form laminin 332, an essential component of struc-
tures called anchoring filaments (AFs). By binding to basal
keratinocyte hemidesmosomes in the dermal/epidermal junction
(DEJ), laminin 332 maintains adherence between the two layers
of the skin (2). Loss of laminin 332 in patients who have H-JEB
results in skin and mucocutaneous blistering, chronic infection,
inadequate feeding, compromised wound healing, and refractory
anemia (2, 3). Collectively, these derangements result in a 73%
mortality rate, and few patients survive past 1 y of life, with death
most commonly due to sepsis, failure to thrive, and respiratory
failure (4–6). To date, there is no cure for H-JEB and thera-
peutic options are limited to palliative care (1, 5), despite various
therapeutic strategies envisioned for JEB, including protein
replacement therapy, bone marrow stem cell transplantation
(SCT), and utilization of gene-corrected keratinocyte autografts
(1, 7–11).
In ∼80% of all H-JEB cases, the LAMB3 gene is affected (12).
Although over 87 different mutations have been identified in H-
JEB, ∼95% of disease-causing alleles contain LAMB3 nonsense
mutations that generate premature termination codons (PTCs),
resulting in mRNA decay and synthesis of either no protein or a
truncated protein incapable of forming functional laminin 332 (1,
12). Strikingly, in a recent review of 65 patients with H-JEB with
known genotypes, the R635X nonsense mutation was detected in
84% of all patients with a mutated LAMB3 gene (1). Thus, this
mutational hotspot is a prime therapeutic target and warrants
evaluation with nonsense mutation suppression therapy.
Aminoglycoside nonsense mutation suppression therapy using
gentamicin has been shown to restore full-length, functional
proteins in several genetic disorders, including cystic fibrosis
(CF), Duchenne’s muscular dystrophy (DMD), hemophilia, and
retinitis pigmentosa (13–16), by mediating PTC readthrough via
impaired codon/anticodon recognition after the aminoglycoside
binds to mammalian ribosomal RNA (17, 18). Our recent work
with recessive dystrophic epidermolysis bullosa (RDEB), a re-
lated mucocutaneous blistering disease caused by mutations in
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the gene encoding for type VII collagen (C7), demonstrated that
gentamicin restored functional C7, which corrected dermal-
epidermal separation, improved wound closure, and reduced
blister formation in patients with RDEB with nonsense muta-
tions (19). Moreover, there is already evidence that readthrough
of H-JEB PTCs may lead to a much milder phenotype and im-
prove clinical outcomes. Pacho et al. (20) showed that a patient
with H-JEB with compound heterozygous nonsense mutations in
the LAMA3 gene (R943X/R1159X) unexpectedly improved with
aging due to spontaneous readthrough of the R943X allele.
In this study, we tested the hypothesis that the aminoglycoside
antibiotic gentamicin might have utility in the treatment of H-JEB
caused by LAMB3 nonsense mutations. We used site-directed
mutagenesis to generate eight known H-JEB nonsense mutations
and transfected these constructs into H-JEB laminin β3-null cells.
Gentamicin treatment of these cells induced PTC readthrough and
production of full-length laminin β3 protein to varying degrees in
all eight nonsense constructs. Using an H-JEB laminin β3-null cell
line engineered to express the R635X (H-JEB1) and C290X (H-
JEB2) nonsense mutations, we show herein that gentamicin is able
to induce PTC readthrough and restore functional laminin β3
protein, which successfully forms functional laminin 332 trimers.
Gentamicin-restored laminin 332 in H-JEB1 and H-JEB2 kerati-
nocytes reversed their abnormal cellular morphology, slow growth
rate, poor cell-matrix adhesion, and hypermotility. Finally, in cul-
tured human skin equivalents (SEs) composed of H-JEB1 and
H-JEB2 keratinocytes, gentamicin treatment restored laminin 332
trimer, which incorporated into the DEJ. Our data demonstrate
that gentamicin can induce PTC readthrough and restore func-
tional laminin β3 protein and, ultimately, laminin 332 trimers in H-
JEB cells with LAMB3 nonsense mutations.
Results
Gentamicin Promotes Readthrough of Multiple H-JEB Nonsense Mutations
and Induces Full-Length Laminin β3. Aminoglycoside-induced PTC
readthrough efficacy is contingent on the type of aminoglycoside
used and the specific sequence of the PTC generated by the non-
sense mutation (18). To date, 20 different nonsense mutations have
been reported in the LAMB3 gene (3). To evaluate the potential
general utility of gentamicin therapy for H-JEB–associated non-
sense mutations, we used site-directed mutagenesis to introduce
eight known H-JEB nonsense mutations into a LAMB3 expression
vector. Fig. 1A is a schematic of the laminin β3 molecule showing
the location of each of the newly introduced nonsense mutations.
We transfected these nonsense mutant constructs into a H-JEB
laminin β3-null cell line, where the underlying defect is not
caused by a nonsense mutation in LAMB3, and prepared cell ly-
sates at 48 h after treatment with gentamicin. We used gentamicin
concentrations of 500 μg/mL, which generated the strongest read-
through activity in the H-JEB cells without affecting cell viability
(SI Appendix, Fig. S1). Gentamicin promoted PTC readthrough of
every LAMB3 nonsense mutant construct tested and resulted in
production of full-length laminin β3 in all cases (Fig. 1B). As de-
termined by densitometry analysis, gentamicin induced varying
degrees of PTC readthrough, leading to laminin β3 expression
between ∼2% and ∼27% (depending on the specific mutation) of
that found in H-JEB cells transiently transfected with the wild-type
LAMB3 expression plasmid. Cells transiently transfected with the
wild-type plasmid express laminin β3 at levels 90% of that seen in
normal immortalized keratinocytes (IKCs) (Fig. 1B). Thus, our
data demonstrate that all eight naturally occurring H-JEB nonsense
mutations tested here are amenable to suppression by gentamicin
in H-JEB cells, but with varying levels of efficacy.
Gentamicin Produces Full-Length Laminin β3 in a Dose-Dependent and
Sustained Fashion. Next, we focused on the two nonsense muta-
tions that exhibited the strongest responses in our transient
transfection experiments for further functional studies: R635X
and C290X. We used lentiviral expression vectors to stably ex-
press these two constructs in H-JEB laminin β3-null cells and
established two cell lines: H-JEB/R635X (H-JEB1) and H-JEB/
C290X (H-JEB2). As shown in Fig. 2A, gentamicin mediated a
dose-dependent induction of full-length, 140-kDa laminin β3,
while untreated cells displayed minimal laminin β3 expression.
The optimal, nontoxic gentamicin concentration that maximized
readthrough and full-length laminin β3 production was 500 μg/mL
in both cell lines. Using this optimized concentration, quantifica-
tion showed that gentamicin induced full-length laminin β3 expres-
sion in H-JEB1 and H-JEB2 to 11.78% and 30.74% of the levels
observed in normal IKCs, respectively (Fig. 2B).
These immunoblot results were confirmed by immunofluo-
rescence analysis. As shown in Fig. 2C, gentamicin-treated cells
revealed positive staining for laminin β3 in both H-JEB1 and
Fig. 1. Gentamicin restored full-length laminin β3 expression in laminin β3-
null H-JEB keratinocytes transfected with multiple cDNA constructs coding
for H-JEB nonsense mutations. (A) The 1,172-aa sequence of laminin
β3 consists of a globular laminin N-terminal (LN) domain, laminin epidermal
growth factor-like (LE) domains, and a laminin coiled-coil (LCC) domain.
Eight LAMB3 nonsense mutants, generated by site-directed mutagenesis, are
shown in the schematic, with the approximate positions of the mutations
indicated by arrows. (B) H-JEB keratinocytes that do not express laminin
β3 were transfected with cDNA expression vectors coding for wild-type (WT)
or various laminin β3 nonsense mutants, as indicated, for 48 h. Cells trans-
fected with LAMB3 nonsense mutations were then incubated with genta-
micin (500 μg/mL) for an additional 48 h. Cell lysates were prepared and then
subjected to 4–12% SDS/PAGE followed by immunoblot analysis using a
monoclonal anti–laminin β3 antibody or an anti–β-actin antibody (loading
control). (Left) First lane represents laminin β3 (Lam-β3) produced from H-JEB
cells transfected with the expression vector for WT Lam-β3 (positive control).
(Right) Comparison of Lam-β3 produced from nontransfected (CON) normal
IKCs with H-JEB cells transfected with the WT expression plasmid. We per-
formed three independent experiments, and similar results were obtained.
(C) ImageJ analysis of laminin β3 expression normalized with β-actin from B.
Results are displayed as a percentage of WT expression.











































H-JEB2, with 28% of H-JEB1 and 67% of H-JEB2 keratinocytes
staining brightly (37% of IKCs stain brightly for laminin β3). In
contrast, there was no detectable staining in either of the untreated
cell groups. Taken together, these data indicate that gentamicin is
capable of mediating PTC readthrough and inducing laminin β3
expression in both H-JEB1 and H-JEB2 cells.
Additionally, to better reflect clinical therapeutic use, we
sought to determine the effects of continued dosing with gen-
tamicin. To accomplish this, H-JEB1 and H-JEB2 cells were
incubated with growth medium that received consecutive daily
supplementation with gentamicin (500 μg/mL) for up to 5 d.
Immunoblot analysis demonstrated that after 5 d of treatment,
full-length laminin β3 expression increased up to 53.34% and
57.24% of the levels seen in normal keratinocytes for H-JEB1
and H-JEB2, respectively (Fig. 3 A and B). No apparent toxicity
was observed with multiple treatments.
Since cells engineered to express exogenous nonsense muta-
tions may respond differently than cells harboring the endoge-
nous mutations would, we conducted experiments with primary
JEB3 cells from a patient heterozygous for a nonsense mutation
[1903C>T (R635X)] and an exonic splice site mutation (3009C-
T) in LAMB3 (21, 22). As shown in SI Appendix, Fig. S2, using
optimal conditions (500 μg/mL and four daily doses), gentamicin
treatment resulted in the production of full-length laminin β3 at
levels 50.5% of those seen in normal human keratinocytes. In
keeping with the previous report, there was minimal basal ex-
pression of laminin β3 in untreated cells (22). We did not observe
any toxicity under these treatment conditions. Therefore, we
conclude that gentamicin-induced readthrough of the endoge-
nous R635X gene in JEB3 behaves similarly to the readthrough
observed using the episomal vector expressing the R635X gene
(H-JEB1). Given the difficulty in culturing these primary cells,
all subsequent studies were conducted using our immortalized
H-JEB cells engineered to stably express nonsense mutations.
We next evaluated how long laminin β3 production could be
maintained after initial administration of gentamicin. As shown
in Fig. 3C, full-length, 140-kDa laminin β3 was detected for up
to 2 wk after initial treatment and levels were stable for both
H-JEB1 and H-JEB2 keratinocytes. Secreted laminin β3 was also
detectable for up to 2 wk in culture (Fig. 3C). Interestingly,
additional experiments revealed that expression of laminin β3
was durable even 6 wk after initial administration (SI Appendix,
Fig. S3). These data indicate that gentamicin-induced PTC
readthrough and production of laminin β3 are sustained well
after initial treatment.
After confirming gentamicin-mediated readthrough in our two
stable H-JEB cell lines, we sought to test other known PTC
readthrough agents and compare their efficacy with gentamicin.
These agents include aminoglycosides, such as paromomycin and
amikacin (23); PTC124 (a nonaminoglycoside PTC readthrough
compound) (24); and amlexanox (an immunomodulatory drug
that was recently reported to induce PTC readthrough via the
inhibition of nonsense-mediated decay of RNA in human cells
with nonsense mutations, including cells originating from pa-
tients with RDEB) (25). Using concentrations from previous
studies that did not affect cell viability (23, 25–27) (SI Appendix,
Fig. S1), none of these compounds induced PTC readthrough
and detectable laminin β3 expression above basal levels in either
H-JEB1 or H-JEB2 (Fig. 4). To confirm these results, we tested
amlexanox at the highest concentrations reported in the litera-
ture in all eight H-JEB nonsense mutation constructs transfected
into H-JEB cells. A marginal level of laminin β3 was detected by
immunoblot analysis of cell lysates with the Q243X mutation, but
no protein was detected with the other seven mutations (SI
Appendix, Fig. S4).
Gentamicin-Induced Laminin β3 Assembles into Laminin 332 Trimers
That Deposit into the Extracellular Space. Laminin β3 associates
with the α3 and γ2 chains to form functional laminin 332 heter-
otrimers that are secreted into the medium in normal cultured
keratinocytes. To determine if gentamicin-induced laminin β3
can contribute to the assembly of mature laminin 332 trimers,
conditioned media from the gentamicin-treated H-JEB1 and
H-JEB2 cells were collected after 72 h, concentrated, and then
subjected to immunoblot analysis with a polyclonal anti-laminin
332 antibody. As shown in Fig. 5A, 440-kDa and 400-kDa dou-
blets (corresponding to the processed and cleaved laminin
332 trimers, respectively, postsecretion) (28) were detected in
Fig. 2. Gentamicin mediates dose-dependent induction of full-length laminin
β3 in laminin β3-null H-JEB keratinocytes stably transfected with the R635X and
C290X nonsense mutation cDNA constructs. (A) Laminin β3 (Lam-β3)-null H-JEB
cells were stably infected with Lam-β3 expression vectors coding for the R635X
and C290X H-JEB–associated nonsense mutations, labeled H-JEB1 and H-JEB2,
respectively. These cells were treated with increasing concentrations of gen-
tamicin (GENT), as indicated, for 48 h. Cell lysates were prepared and then
subjected to 4–12% SDS/PAGE, along with control lysates from normal IKCs,
followed by immunoblot analysis with a monoclonal anti–Lam-β3 antibody or
an anti–β-actin (loading control) antibody. GENT induced full-length Lam-
β3 production in a dose-dependent manner in both mutant cell lines. Three
independent experiments were performed with similar results. (B) ImageJ
analysis of laminin β3 expression normalized with β-actin from A. Results
are displayed as a percentage of IKC expression. (C) H-JEB1 and H-JEB2
keratinocytes were either untreated or treated with GENT (500 μg/mL) for
48 h and then subjected to immunofluorescence staining with a monoclonal
anti-laminin β3 antibody. Note that GENT induced laminin β3 expression in
both H-JEB1 and H-JEB2 keratinocytes. In contrast, untreated H-JEB1 and H-
JEB2 keratinocytes lacked laminin β3 staining, similar to parental H-JEB cells.
IKCs served as a positive control. Images (magnification, 40×) are representa-
tive of eight independent experiments.
































the media from gentamicin-treated H-JEB1 and H-JEB2, re-
spectively, similar to those seen in normal human keratinocytes.
In contrast, no trimer was detected in the media of the untreated
cells. These findings suggest that the gentamicin-induced laminin
β3 is capable of forming trimers that are properly cleaved to
mature laminin 332 in the extracellular space.
Immunoblot results were further confirmed by immunofluo-
rescent analysis using a polyclonal antibody recognizing native
laminin 332. As shown in Fig. 5B, without gentamicin treatment,
there is virtually no secreted laminin 332 trimer detectable from
H-JEB1 and H-JEB2 cells when probed with anti-laminin 332
antibody. In contrast, immunostaining of gentamicin-treated
cells displayed not only increased intracellular laminin expres-
sion but also deposition of laminin 332 into the surrounding
extracellular matrix (ECM), although the amount of deposited
laminin 332 was significantly lower than that of normal keratino-
cytes. Taken together, these data suggest that gentamicin-induced
laminin β3 contributes to the formation of mature laminin 332.
Gentamicin Normalizes the Morphology, Proliferation Rates, Poor
Cell-Matrix Adhesion, and Hypermotility of H-JEB Cells. Gentami-
cin’s suppressive effects on PTCs are mediated by a mispairing
between the stop codon and near-cognate aminoacyl tRNA,
resulting in insertion of a random amino acid instead of chain
termination (17, 18). Since the amino acid inserted at the PTC
may differ from the residue originally residing in wild-type
laminin β3, the readthrough product may have impaired func-
tionality compared with the normal wild-type protein. For this
reason, we evaluated whether the laminin 332 produced after
gentamicin treatment of H-JEB cells is actually functional. It has
previously been shown that JEB cells display abnormal cellular
phenotypes, including abnormal morphology, poor growth po-
tential, and reduced cell adhesion (29). As shown in Fig. 6A,
under light microscopy, we observed that ∼66% of keratinocytes
cultured from the H-JEB parent cells are polymorphic and show
multiple morphological abnormalities, including unusual, elon-
gated, spindle-shaped cells as well as rounder cells with enlarged
cytoplasm, compared with keratinocytes cultured from normal
controls (2% abnormal). In contrast, treatment with gentamicin
reduced the high percentage of cells with irregular morphology in
untreated H-JEB1 and H-JEB2 cells to that approaching normal
keratinocytes (4% and 6% abnormal, respectively). Untreated H-
JEB1 and H-JEB2 keratinocytes maintained all of the morpho-
logical abnormalities of the H-JEB parent cells. These findings
suggest that gentamicin treatment reverses the abnormal mor-
phology of H-JEB cells.
We next determined if gentamicin-induced laminin 332 could
correct the poor growth potential of H-JEB cells. As shown in
Fig. 6B, compared with normal keratinocytes, H-JEB parent cells
demonstrated a significantly reduced growth rate, as previously
described (29). In contrast, gentamicin treatment of H-JEB1 and
H-JEB2 keratinocytes enhanced their growth potential to levels
approaching normal keratinocytes.
Additionally, we evaluated whether treatment with gentamicin
can enhance the faulty cell-substratum adhesion of H-JEB cells.
We subjected normal keratinocytes, as well as H-JEB1 and H-
JEB2 keratinocytes (either untreated or treated with gentami-
cin), to a well-established kinetic cell-detachment assay. Fig. 6C
Fig. 3. Gentamicin-induced production of full-length laminin β3 is sustained
and increases with continued dosing in H-JEB keratinocytes stably trans-
fected with the R635X and C290X nonsense mutation cDNA constructs. (A)
H-JEB1 and H-JEB2 keratinocytes were incubated with growth medium in
the absence of gentamicin (GENT) or were given consecutive daily treat-
ments (Tx) of GENT (500 μg/mL) for up to 5 d. Cell lysates were prepared and
then subjected to 4–12% SDS/PAGE, followed by immunoblot analysis with a
monoclonal anti-laminin β3 (Lam-β3) antibody or an anti–β-actin (loading
control) antibody. Note that GENT-induced, full-length Lam-β3 expression
increased with daily treatment. We performed three independent experi-
ments with similar results. (B) ImageJ analysis of laminin β3 expression nor-
malized with β-actin in lysates from A. Results are displayed as a percentage
of IKC expression. (C) H-JEB1 and H-JEB2 keratinocytes were incubated with
growth medium in the absence or presence of GENT (500 μg/mL) for 48 h,
which were then changed to normal growth medium for the duration of the
experiment. Cell lysates (Lysate) and conditioned media (CM) were prepared
at various days after treatment, as indicated, and then subjected to 4–12%
SDS/PAGE followed by immunoblot analysis with a monoclonal anti–Lam-
β3 antibody or an anti–β-actin (loading control). Lysate and CM from day
7 untreated cells (NT) were run as negative controls. Note that GENT induced
sustained Lam-β3 production that was readily detectable 2 wk after initial
treatment. We performed three independent experiments with similar results.
Fig. 4. Efficacy of various readthrough compounds in inducing laminin β3
(Lam-β3) production. H-JEB1 and H-JEB2 keratinocytes were untreated
(NT) or treated with gentamicin (GENT; 500 μg/mL), paromomycin (PARO;
2,000 μg/mL), amikacin (AMIK; 1,000 μg/mL), PTC124 (20 μg/mL), and amlexanox
(AMX; 7.5 μg/mL), as indicated, for 48 h. Cell lysates were prepared and then
subjected to 4–12% SDS/PAGE, followed by immunoblot analysis with a
monoclonal anti–Lam-β3 antibody or an anti–β-actin (loading control). Note
that no drug except GENT promoted significant readthrough and production
of Lam-β3 over basal levels. We performed three independent experiments,
and similar results were obtained.











































depicts the number of cells detached from the substratum 5 min
after the addition of trypsin, expressed as a percentage of the
total number of cells for each cell type and treatment. Untreated
H-JEB cells exhibited poor cell-substratum adhesion, with over
80% of cells detaching at 5 min compared with normal kerati-
nocytes, which exhibited less than 5% detachment. Conversely,
gentamicin-induced laminin 332 in the treated H-JEB cells en-
hanced their cell-matrix adhesion strength to a degree similar to
that seen in normal keratinocytes. These data indicate that
gentamicin-induced functional laminin 332 can correct the poor
substrate adhesion associated with H-JEB cells.
We have previously shown that RDEB cells demonstrated
hypermotility compared with normal human keratinocytes (30).
To determine if H-JEB cells also exhibit the same phenotype
and, if so, whether gentamicin-induced laminin 332 can reverse
their hypermotility, we subjected normal, parental H-JEB, and
H-JEB1 and H-JEB2 keratinocytes, either untreated or treated
with gentamicin, to a well-established keratinocyte migration
assay. Fig. 6D, Top shows representative microscopic fields of
these cells. Untreated H-JEB1 and H-JEB2 keratinocytes ex-
hibited cellular hypermotility that was identical to laminin β3-
null H-JEB parent cells. We measured cellular motility using a
published, computer-assisted migration index (MI), which is
calculated as the percentage of the microscopic field consumed
by motility tracks (30) (Fig. 6D, Bottom). Interestingly, H-JEB
cells displayed enhanced motility with MIs of 35.6 in comparison
to MIs of 23.2 for normal human keratinocytes. In contrast,
gentamicin-treated H-JEB1 and H-JEB2 keratinocytes exhibited
normalized cellular motility with MIs of 24.07 and 22.92, re-
spectively, similar to normal human keratinocytes. Therefore,
gentamicin effectively promoted PTC readthrough and produced
functional laminin 332 that corrected the hypermotility of H-
JEB cells.
Gentamicin-Induced Laminin 332 Trimers Localize to the DEJ of H-JEB SEs.
After achieving restoration of laminin 332 in H-JEB1 and H-JEB2
keratinocytes and demonstrating correction of H-JEB–associated
abnormal cellular phenotypes, we sought to determine if gentamicin-
induced laminin 332 could incorporate into the DEJ. To test this,
we used an in vitro 3D SE model, where an acellular collagen gel
was infused with normal human fibroblasts and then seeded with
keratinocytes, as described previously (31). In this series of ex-
periments, the SEs were constructed with normal keratinocytes
or with H-JEB1 or H-JEB2 keratinocytes, and they were either
treated with gentamicin or untreated. Up to 2 wk after the SEs
were established in culture, they were subjected to hematoxylin
and eosin staining (SI Appendix, Fig. S5) and immunofluorescence
staining using a polyclonal anti-laminin 332(β) antibody that rec-
ognizes the β3 chain. As seen in the first row of Fig. 7A, there was
no detectable laminin 332 deposition in SEs generated from un-
treated H-JEB1 and H-JEB2 cells. In contrast, there was strong
linear staining at the DEJ between the keratinocytes and the
dermal equivalent in the SEs generated from gentamicin-treated
H-JEB1 and H-JEB2 cells. This pattern was similar to SEs com-
posed of normal human keratinocytes and fibroblasts. To confirm
if this linear deposition was actually within the DEJ, the SE sec-
tions were colabeled with a monoclonal anti-laminin 332(α) anti-
body along with either anti-α6 integrin or anti-β4 integrin antibodies
targeting the α6β4 integrin, an adhesion molecule located in basal
keratinocytes that acts as the nucleating center for hemidesmosome
Fig. 5. Gentamicin-induced laminin β3 organizes into functional laminin 332 trimers that deposit into the extracellular space. (A) H-JEB1 and H-
JEB2 keratinocytes were either untreated (−) or treated (+) with gentamicin (500 μg/mL) for 72 h. Concentrated conditioned media were prepared and
then subjected to 4–12% SDS/PAGE followed by immunoblot analysis using a polyclonal anti-laminin 332 antibody. Concentrated conditioned medium from
IKC cells was run as a positive control. α3*β3γ and α3*β3γ* represent cleaved laminin 332 trimers after extracellular processing. Note that laminin 332 trimers
(of 440 kDa and 400 kDa) were detected in the media of H-JEB1 and H-JEB2 cells treated with gentamicin, which were absent in untreated samples. (B) H-
JEB1 and H-JEB2 keratinocytes were either untreated or treated with gentamicin (GENT; 500 μg/mL) for 48 h and then subjected to immunofluorescence
staining with a polyclonal anti-laminin 332(β3) antibody. Note that GENT induced laminin 332 deposition, which was detected in the ECM (yellow arrowheads)
in both H-JEB1 and H-JEB2 cells. In contrast, untreated H-JEB cells lacked laminin 332 expression. H-JEB keratinocytes were included as an additional negative
control, and normal IKC cells were used as a positive control. Images (magnification, 40×) are representative of six independent experiments.
































formation in normal skin (32). Coimmunolabeling of SEs composed
of H-JEB1 and H-JEB2 cells treated with gentamicin revealed
strong linear staining of both integrins and laminin 332 colocalized
at the DEJ between the keratinocytes and the dermal equivalent. In
contrast, SEs generated from untreated H-JEB1 and H-JEB2 cells
displayed only intracellular staining, and no linear staining, at the
DEJ. It is possible that the formation of laminin 332 trimer is a
prerequisite for correct localization of α6β4 integrin to the DEJ.
Quantitation with ImageJ (NIH) analysis showed that the level of
laminin 332 deposited at the DEJ in SEs composed of gentamicin-
treated H-JEB1 and H-JEB2 keratinocytes was 74.5% and 78.4%,
respectively, of the level of laminin 332 produced from SEs com-
posed of normal keratinocytes. We conclude that gentamicin-
induced laminin 332 is capable of incorporating into the DEJ
in vitro.
Discussion
In this study, we tested eight known nonsense mutations affect-
ing LAMB3 and found that gentamicin promoted varying de-
grees of PTC readthrough in H-JEB keratinocytes transfected
with these mutations. Two mutations were selected for further
functional studies due to prevalence (R635X) and location on
the ECM-binding domain of laminin β3 (C290X). We further
demonstrated that gentamicin promoted PTC readthrough in
H-JEB cells harboring these two mutations, ultimately resulting
in production of functional laminin 332 that corrects H-JEB–
associated abnormal cellular phenotypes and deposits into the
DEJ of SEs. There are at least 20 reported unique LAMB3
nonsense mutations associated with H-JEB; thus, our data may
not reflect all potential responses in patients harboring other
types of nonsense mutations. It should be emphasized, however,
that three nonsense mutations investigated here, R42X, Q243X,
and R635X, are recurrent mutations in patients with H-JEB
and account for ∼60% of all patients with H-JEB and 74% of
patients with H-JEB who have nonsense mutations (1).
It has been reported that the type of stop codon (in order of
propensity for readthrough: UGA, UAG, UAA) and the nearby
nucleotide sequence context surrounding each stop codon (i.e.,
the immediate upstream −1 nt and downstream +4 nt) are major
factors in determining readthrough efficacy for a given PTC. In
particular, the nucleotide C or U at the −1 position and the
nucleotide C at the +4 position flanking the PTC promote
stronger readthrough efficiency compared with other nucleotides
at those respective positions (20, 33, 34). Although we did not
perform a systematic analysis where artificial mutations were
created in the local nucleotide context of each H-JEB PTC, as
described elsewhere (20, 33, 34), our data support the impor-
tance of the −1 and +4 positions in determining the readthrough
efficacy in seemingly identical H-JEB stop codons. The stop
codons and nucleotide context of each of the eight H-JEB–
associated PTCs (six UGA and two UAG) analyzed in this
study are summarized in SI Appendix, Table S1. In examining the
two UAG stop codons, the presence of a C in the +4 position of
Q243X is the only difference that may offer an explanation for its
order-of-magnitude greater response to gentamicin compared
with Q586X. Also, although none of the six mutations bearing
the UGA stop codon (R42X, R144X, C290X, W610X, R635X,
and R660X) have the consensus optimal C in the +4 position,
the strongest responders tended to have either a C or U in the −1
position (R635X and C290X), both of which are predicted to
be the preferred nucleotides for readthrough (20, 34). It should
be pointed out, however, that the limited number of mutations
analyzed here lacks the necessary statistical power to make any
definitive conclusions regarding the relationship between read-
through efficacy and the type of PTC or surrounding nucleotides.
The ultimate goal of any H-JEB therapy is to generate ade-
quate levels of functional laminin 332 that properly localizes to
the DEJ of the patients’ skin and provides sufficient adherence
between the epidermis and dermis. In our studies of RDEB, we
observed that gentamicin induced PTC readthrough and re-
stored C7 at the DEJ to levels more than 50% of normal human
skin. Several lines of evidence show that only 35% of normal is
sufficient to provide good epidermal-dermal adherence in
RDEB (35, 36). Although the minimum amount of laminin 332
secreted by cells required to restore epidermal-dermal adher-
ence is not known, a study analyzing keratinocytes and skin bi-
opsies collected from a patient with H-JEB with spontaneous
LAMA3 PTC readthrough provides some insight (20). Although
this patient’s keratinocytes secreted significantly less laminin
α3 than healthy controls in cell culture, he continued to experi-
ence clinical improvement, with laminin 332 levels in his DEJ
Fig. 6. Gentamicin normalizes the cell morphology, cellular proliferation,
substratum attachment, and hypermotility of H-JEB cells. (A) Under light
microscopy, the morphology of H-JEB keratinocytes is corrected by genta-
micin (GENT). (Top Left) Cultured normal IKCs show a compact, typical epi-
thelial cell morphology. (Top Right) H-JEB keratinocytes, in contrast, exhibit
a mixture of cell morphologies, with some cells displaying an elongated,
spindle-shaped morphology, while other cells have a rounder shape with
enlarged cytoplasm. Note that many cells also appear poorly attached to
the culture plate. (Bottom Left and Bottom Right) H-JEB1 and H-JEB2
keratinocytes treated with GENT display a more typical epithelial cell mor-
phology reminiscent of normal human keratinocytes. (Scale bars: 100 μm.)
(B) IKCs, laminin β3-null H-JEB keratinocytes, and GENT-treated H-JEB1 and
H-JEB2 keratinocytes were seeded to plates with an initial cell count of 75,000.
Keratinocytes were then incubated in growth medium for 48 h and supple-
mented with GENT (500 μg/mL) where indicated. After 48 h, the plates were
trypsinized and the cells were counted. (C) IKCs, laminin β3-null H-JEB kerati-
nocytes, H-JEB1 keratinocytes, and H-JEB2 keratinocytes were seeded onto tis-
sue culture plates. The H-JEB1 and H-JEB2 keratinocytes were treated with
GENT (500 μg/mL) for 48 h. All cells were simultaneously trypsinized, and the
number of cells detached after 5 min was determined and expressed as a
percentage of the total number of cells for each cell line. After 5 min, H-JEB cells
were nearly completely detached, while IKCs and treated H-JEB1 and H-
JEB2 keratinocytes exhibited less than 10% detachment. Each value is the av-
erage of triplicates from three independent experiments. (D) H-JEB keratino-
cytes were either untreated or treated with GENT (500 μg/mL) for 48 h and then
subjected, along with IKCs and laminin β3-null H-JEB parent keratinocytes, to a
colloidal gold salt migration assay using collagen I as a matrix. (Top) Repre-
sentative fields photographed at a magnification of 40× under dark-field optics.
(Bottom) Computer-generated migration index is the percentage of the total
field area occupied by migration tracks. Error bars indicate SEs of three dif-
ferent experiments. Note that H-JEB keratinocytes were hypermotile compared
with IKCs. In contrast, GENT-treated H-JEB1 and H-JEB2 cells demonstrated re-
duced motility similar to the motility of IKCs. Untreated H-JEB1 and H-
JEB2 keratinocytes exhibited cellular hypermotility that was identical to lam-
inin β3-null H-JEB parent cells.











































eventually approaching those of a normal control. This suggests
that, although not precisely quantified, the amount of laminin
332 secreted from keratinocytes required to restore normal ex-
pression at the DEJ and maintain dermal-epidermal adherence
may be significantly less than that produced by normal kerati-
nocytes. In the present study, we observed that two administra-
tions of gentamicin induced PTC readthrough in H-JEB1 and
H-JEB2 cells to levels of 12.76% and 28.46% of those seen in
normal cells, respectively. Most importantly, after 5 d of daily
gentamicin dosing in both H-JEB keratinocytes, the levels of
laminin β3 increased to more than 50% of those seen in normal
keratinocytes. Additionally, even without continued dosing, the
level of full-length laminin β3 was maintained without dimin-
ishing for up to 4 wk after the initial two treatments. Given this
robust response to short-term gentamicin treatment and the
durability of laminin β3 detected in media and cell lysates, it is
possible that short-term, pulsed gentamicin therapy might be
sufficient to provide enough laminin 332 to improve the clinical
phenotype of a patient with H-JEB.
Alternative therapeutic approaches to treat JEB are currently
being explored, including allogenic SCT and autologous trans-
genic skin graft therapy. Allogenic SCT via bone marrow or
peripheral blood harvesting has advanced to clinical trials, but a
retrospective study evaluating the treatment of infants with se-
vere H-JEB found only limited short-term efficacy in two pa-
tients before they died (1). In a recent study by Hirsch et al. (10),
autologous gene-corrected, transgenic keratinocytes were grafted
onto large open wounds of a 7-y-old child. The grafted skin
remained closed, resisted mechanical stress, and continued to
express laminin 332 for at least 21 mo. While promising, a less
expensive treatment, such as topical or systemic gentamicin, might
benefit patients with H-JEB who have nonsense mutations,
while also being readily available. In addition, gentamicin
applied topically or systemically would not expose the patient
to live cells or viral vectors and would not involve surgical
procedures.
Gentamicin is a well-characterized antibiotic that is approved
by the US Food and Drug Administration for infections, and its
potential side effects (ototoxicity and/or renal impairment) can
be easily monitored and prevented. Moreover, in patients with
RDEB who have nonsense mutations, we recently demonstrated
that topical and intradermal gentamicin proved to be both safe
and effective (19). Nonetheless, other nonaminoglycoside de-
rivatives with potentially greater PTC readthrough or fewer side
effects than gentamicin have been reported, two of which are
PTC124 (ataluren) and amlexanox (25, 37, 38). While PTC124
showed promise in preclinical experiments for CF and DMD,
subsequent clinical trials in patients with CF and DMD, as well
as the in vitro results from this study and data from other disease
models, including RDEB, demonstrated limited or no ability of
PTC124 to induce PTC readthrough (26, 37–43). Amlexanox has
recently been shown to enhance PTC readthrough and restore
C7 expression in some RDEB cells (25). However, in our present
study, we found that amlexanox was only able to induce laminin
Fig. 7. Gentamicin-induced laminin 332 incorporates into the DEJ of in vitro SEs. (A) Cryosections from 1-wk-old SEs were subjected to immunofluorescent
labeling using a polyclonal anti-laminin 332(β3) antibody [Lam-332(β); row 1] and a monoclonal anti-laminin 332(α3) antibody [Lam-332(α), row 2], and were
then colabeled with antibodies to either the α6 integrin chain (α6 Integrin, row 3) or the β4 integrin chain (β4 Integrin, row 4). From left to right, the columns
represent SEs established from normal IKCs and untreated and treated (500 μg/mL gentamicin; GENT) H-JEB1 and H-JEB2 cells. Results are representative
images from triplicate SEs. Note that the antibodies to both the α6 integrin and β4 integrin colocalize with the labeling of the Lam-332(α) antibody. (B) Mean
average fluorescence intensity of laminin 332 (Lam-332) immunoreactivity was obtained from representative images from three independent SEs. Frozen
sections were probed with a polyclonal laminin 332(β3) antibody, and the intensity of Lam-332 at the DEJ of each specimen was measured by computer-
assisted ImageJ software and compared with the intensity of Lam-332 in SEs derived from IKCs. Values represent the intensity of Lam-332 in the DEJ of the SEs
expressed as a percentage of the average intensity obtained from IKCs (100%). Data represent the mean ± SD.
































β3 expression in one of eight H-JEB–transfected nonsense muta-
tions. Additionally, we failed to detect readthrough activity using
two other aminoglycosides: amikacin and paromomycin. This is
consistent with other previously published reports (26, 44–46).
In summary, this study demonstrates that gentamicin-induced
suppression of H-JEB PTC mutations restores laminin β3 ex-
pression and formation of functional laminin 332 that incorpo-
rates into the DEJ. The future goals of our research involve
advancing gentamicin into human clinical trials and identifying
more advantageous modes of delivery. The many disparate organ
systems affected by H-JEB make i.v. infusion an ideal route for
administering gentamicin, but topical administration and nebu-
lized administration are alternative therapies that present less
systemic exposure while targeting the skin and lungs, two critical
organ systems whose pathological involvement is associated with
H-JEB’s high infant mortality (16, 19, 47). Ultimately, genta-
micin therapy may hold great promise for the 80% of patients
with H-JEB who harbor nonsense mutations, as well as for sup-
pressing PTCs in other inherited skin conditions due to nonsense
mutations.
Materials and Methods
Cell Lines and Culture Conditions. The human embryonic kidney cell line 293T
(American Type Culture Collection) was cultured in Dulbecco’s modified essential
medium (DMEM) supplemented with 10% FBS. An immortalized H-JEB kerati-
nocyte cell line harboring a laminin β3-null mutation was cultured in serum-free
keratinocyte growth medium supplemented with human keratinocyte growth
supplement (HKGS) (Epilife; GIBCO BRL) (48, 49). Primary human keratinocytes
were purchased from Thermo Fisher Scientific. Primary JEB3 keratinocytes from
a patient heterozygous for a nonsense mutation [1903C>T (R635X)] and an
exonic splice site mutation (3009C-T) in LAMB3were obtained with the approval
of the University Hospital of the Paracelsus Medical University, Salzburg after
written informed consent was given by the patient, as described previously (21,
22). Normal human or H-JEB keratinocytes were immortalized using the E6 and
E7 genes of human papillomavirus type 6 as described elsewhere (50). All H-JEB
cells, both primary and immortalized, were plated and cultured on collagen
1-coated plates and grown with Epilife, as described above. Adult normal
primary dermal fibroblasts were purchased from Thermofisher Scientific and
cultured in DMEM/Ham’s F-12 (1:1) supplemented with 10% FBS. Primary fi-
broblasts were passaged as they reached confluence, and all SE experiments
were performed using fibroblasts between passages 4 and 6.
Site-Directed Mutagenesis, Cell Transfection, and Cell Transduction. Site-
directed mutagenesis was performed on LAMB3 cDNA in the pRC/CMV
vector using a commercial kit (QuikChange II Site-Directed Mutagenesis Kit;
Stratagene, Inc.) according to the manufacturer’s instructions, as described
previously (30). Briefly, a pair of complementary primers with 39 bases was
designed, and a mutation to change specific amino acid residues to a stop
codon was placed in the middle. We generated primers for the following
eight mutations associated with H-JEB reported in the literature: R42X,
R144X, Q243X, C290X, Q586X, W610X, R635X, and R660X. Parental cDNA
inserted in pRC/CMV was amplified using Pyrococcus furiosus DNA poly-
merase with these primers for 16 cycles in a DNA thermal cycler. After di-
gestion of the parental DNA with DpnI, the amplified DNA with the
nucleotide substitutions incorporated was transformed into Escherichia coli
(XL1-Blue). The mutations were confirmed by automated DNA sequencing.
The expression vector encoding wild-type or mutant LAMB3 cDNA was
used to transfect H-JEB cells using Lipofectamine LTX with Plus Reagent (Life
Technologies). Cells were plated and transfected according to the manu-
facturer’s instructions. Twenty-four hours after transfection, the medium
was changed to fresh growth medium containing gentamicin for 48 h.
To further investigate the short- and long-termeffects of gentamicin andother
readthrough compounds on laminin β3-null H-JEB cells harboring the R635X and
C290X nonsense mutations, we stably transduced LAMB3 expression vectors for
those mutations into parent H-JEB laminin β3-null cells and established the
H-JEB1 and H-JEB2 cell lines, respectively. Briefly, DNA containing the entire
LAMB3 coding sequence was cloned into the pRRLsinhCMVGFPpre viral ex-
pression vector used previously (30). After confirmation of correct incorporation
with automated DNA sequencing, vectors were transfected along with pΔR and
VSV-G packaging vectors into 293T cells. Active virus was harvested and sup-
plemented to H-JEB cells, with an overall infection rate of greater than 90% for
each construct.
Drug Treatment and Immunoblotting. In experiments where an aminoglyco-
side or PTC124 (Selleckchem) was used to induce PTC readthrough, normal
human keratinocytes or H-JEB cells were transiently transfected with cDNA
expression constructs containing nonsense mutations at 60–70% confluence.
Twenty-four hours after transfection, the media were replaced and sup-
plemented with or without gentamicin (Sigma), paromomycin (Sigma),
amikacin (Sigma), or PTC124 for 48 h.
To determine the cellular expression of laminin β3 protein, cellular extracts
were prepared 48 h after incubating with gentamicin as described and sub-
jected to 4–15% SDS/PAGE (Bio-Rad). Proteins were then electrotransferred
onto a nitrocellulose membrane. The presence of laminin β3 monomer was
detected with monoclonal anti-laminin β3 antibodies (Anti-Kalinin B1, clone 17;
BD Biosciences). The presence of laminin 332 trimer was detected with either
polyclonal anti-laminin 332 (β) chain antibodies (Anti-Laminin β3/Laminin 5;
Origene) or monoclonal anti-laminin 332 (γ) chain antibodies [Anti-Laminin-5
(g2 chain), clone D4B5; EMD Millipore] followed by secondary antibodies using
either horseradish peroxidase-conjugated goat anti-rabbit IgG or anti-mouse
IgG and an enhanced chemiluminescence detection reagent (GE Healthcare).
To determinewhether gentamicin-induced laminin 332 is secreted into the
medium, the cells were treated with gentamicin for 48 h. The media were
then collected and concentrated 10- to 15-fold using Amicon Ultra-4 Cen-
trifugal Filters (Merck Millipore). Samples were then subjected to 4–12% SDS/
PAGE followed by immunoblot analysis, as described above.
To evaluate the effects of gentamicin administration frequency on
H-JEB1 and H-JEB2 cells, growth media were supplemented for the standard
48 h used in previous experiments. After 48 h, the media were supplemented
daily with gentamicin for up to three additional days as indicated. Respective
lysates and media were collected 24 h after their last indicated gentamicin
treatment.
The sustainability of a single course of gentamicin on H-JEB1 and H-
JEB2 cells was evaluated after treatment with gentamicin for the standard
48 h used previously. Media were then changed to fresh media without
gentamicin for the duration of the experiment. Growthmediumwas replaced
every other day until the conclusion of the experiment.
Cellular extracts were prepared and conditionedmedia were collected and
concentrated as described above for evaluation at various time points for
laminin β3 expression. These samples were subjected to 4–12% SDS/PAGE
followed by immunoblot analysis, as previously described (26).
Cell Morphology and Proliferation Assay. We studied cellular morphology
using a Leica DMIL LED inverted microscope (10× lens) equipped with a Leica
DFC340 FX digital camera to digitally capture the images.
To assess the effects of gentamicin on H-JEB cell proliferation, H-JEB
keratinocytes with stably integrated cDNA expression constructs contain-
ing nonsense mutations or normal human keratinocytes were seeded to
uncoated, 24-well plates in quadruplicate at a density of 75,000 keratinocytes
per well. Twenty-four hours after seeding, the media were changed to media
containing gentamicin (0–1 mg/mL) where appropriate. At 48 h, cells were
collected by trypsinization and incubated with 0.2% trypan blue, and live
cells were manually counted.
Cell Viability. To evaluate gentamicin cytotoxicity, H-JEB1 and H-JEB2 kera-
tinocytes were seeded to an uncoated, 96-well plate at a density of 1 × 104
cells per well in 100 μL of culture medium. Twenty-four hours later, media
were changed and supplemented with gentamicin at indicated concentra-
tions from 0 to 2 mg/mL or with amlexanox from 0 to 60 μg/mL (0–200 μM).
Plates were allowed to incubate for 48 h. A freshly prepared solution of
4 mg 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-5[(phenylamino)carbonyl]-
2H-tetrazolium hydroxide (XTT; VWR) in 4 mL of culture medium was mixed
with 10 μL of phenazine methosulfate (PMS; Sigma) solution (3 mg of PMS in
1 mL of PBS), and 25 μL of the combined XTT/PMS solution was directly
added to each 100-μL cell culture (51). Cultures were incubated for 4 h at
37 °C, and absorbance was read at 450 nm.
Cell Detachment. To determine the degree of gentamicin-induced cellular
adherence, a trypsin-based detachment assay was employed (52). Briefly,
normal human keratinocytes and H-JEB, H-JEB1, and H-JEB2 keratinocytes
were seeded on 24-well tissue culture plates at a density of 1 × 104 cells per
well. Twenty-four hours after seeding, the medium was changed to one
containing gentamicin (500 μg/mL) where appropriate. After 72 h, 250 μL of
trypsin/EDTA was added to each well, and any detached cells were removed
after 5 min and counted. An additional 250 μL of trypsin/EDTA was added,
and all remaining cells were allowed to detach and then counted. The
percentages of cells detached were obtained, and the averages and SDs
from nine independent wells for each condition per cell line were calculated.











































Cell Migration. Cell migration was assessed as previously described (53).
Briefly, colloidal gold salts were immobilized on coverslips and coated with
type I collagen (15 μg/mL). Normal human keratinocytes, untreated parental
H-JEB keratinocytes, or gentamicin-treated H-JEB1/H-JEB2 keratinocytes
were suspended, plated on the coverslips, and allowed to migrate for 16–
20 h. The cells were fixed in 0.1% formaldehyde in PBS and examined under
dark-field optics with a video camera attached to a computer equipped with
image capture capability. The computer analyzes 15 nonoverlapping fields
in each experimental condition with NIH Image 1.6 and determines the
percentage area of each field consumed by cell migration tracks (MI). Con-
firmation of a difference in migration as statistically significant requires
rejection of the null hypothesis of no difference between mean MIs obtained
from replicate sets at the P = 0.05 level with a Student’s t test.
Immunofluorescence Staining of Cell Cultures. Normal human keratinocytes
and H-JEB1/H-JEB2 keratinocytes previously treated (500 μg/mL gentamicin) or
untreated were plated in TissueTek chamber slides (Nunc, Inc.) on polylysine at
37 °C for 18 h. Cells were immersed in periodate-lysine-paraformaldehyde fix-
ative for 10 min at room temperature, washed several times with PBS to remove
fixative, and then permeabilized and blocked by incubating in PBS with 3%
BSA, 1% saponin, and 10% normal goat serum for 15 min at room temperature.
The cells were incubated with one of two affinity-purified antibodies: mono-
clonal anti-laminin β3 antibodies at a 1:1,000 dilution or polyclonal anti-laminin
332(β) chain antibodies at a 1:800 dilution. Incubation occurred in a humidified
chamber for 2 h, and cells were then washed three times with PBS and 1%
saponin; they were subsequently counterstained with an FITC-conjugated goat
antibody to mouse IgG (1:1,000; Organon Teknika-Capel) or CY3-conjugated
goat antibody to rabbit (1:1,000; Organon Teknika-Capel) for 1 h and then
washed. The cells were then examined and photographed with a Zeiss epi-
luminating immunofluorescence microscope. All images were photographed
using the same camera and at identical exposure times.
Establishment of in Vitro Organotypic SEs and Immunofluorescence Microscopy.
Establishment of an in vitro skin coculture model was performed as previously
described (31). Briefly, DMEM medium (Corning, Discovery Labware) contain-
ing human dermal fibroblasts (1 × 106 cells per milliliter) was mixed with rat
tail collagen 1 solution (2.5 mg of collagen per milliliter; Corning, Discovery
Labware) and 10× DMEM (Corning, Discovery Labware). This solution was
neutralized with sodium bicarbonate, 1 mL of this solution was distributed
into each 12-well insert (ThinCerts 12-well, 3 μM pore size; Greiner Bio-One),
and the gels were allowed to polymerize. The fibroblast-infused collagen gel
was then submerged in serum-free DMEM and incubated for 24 h. The DMEM
medium was then removed, and each dermal equivalent was covered with
50 μL of 50 μg/mL fibronectin (Sigma) in ultrapure water solution and allowed to
incubate for 30 min. In the meantime, IKCs, H-JEB1 (pretreated with genta-
micin or untreated), and H-JEB2 (pretreated with gentamicin or untreated)
were resuspended in Epilife media supplemented with HKGS + 5% FCS
(Thermo Fisher Scientific) at a concentration of 1 × 106 cells per milliliter. Cells
in this solution were seeded onto each gel and incubated for 45 min to allow
cells to adhere. Afterward, the gels were submerged in Epilife media supple-
mented with HKGS + 5% FCS and cultured for up to 2 wk with descending FCS
concentrations (5%, 2%, and 0% FCS) every 2–3 d when media changes oc-
curred, with gentamicin supplementation where appropriate. Between days
7 and 14 after keratinocyte seeding, SEs were extracted and placed on nitro-
cellulose strips after being soaked in PBS. SEs harvested within this time frame
typically display an epidermis with a thickness of one to two keratinocytes (31).
The SEs were soaked in 50% sucrose solution for 90 min and then slow-frozen
on a metal plate over dry ice. Frozen SEs were mounted in optimum cutting
temperature compound (OCT) and frozen. Five-micrometer-thick sections from
the OCT-embedded SEs were cut using a cryostat, fixed for 5 min in cold ac-
etone, and air-dried. Immunolabeling of SEs was performed using standard
immunofluorescence methods, as described previously (54). SE sections were
labeled with either polyclonal anti-laminin 332(β) chain antibodies followed by
a CY3-conjugated goat anti-rabbit IgG (1:1,000) or colabeled with monoclonal
anti-laminin 332(α) chain antibodies (anti-hLaminin-α3, clone P3H9-2; R&D
Systems) and either polyclonal anti-Integrin β4 (Santa Cruz Biotechnology) or
monoclonal rat anti-Integrin α6 (Santa Cruz Biotechnology) antibodies fol-
lowed by FITC-conjugated goat antibody to mouse IgG (1:1,000 dilution) and
CY3-conjugated goat-anti rabbit (1:1,000 dilution) or CY3-conjugated goat-
anti rat (1:1,000 dilution), respectively. Representative photographs from
stained sections were taken using a Zeiss Axioplan fluorescence microscope
equipped with a Zeiss Axiocam MRM digital camera system. All images were
photographed using the same camera and at identical exposure times. Mean
fluorescence intensity at the DEJ was calculated for each sample using ImageJ
(NIH; https://imagej.nih.gov/ij/), as described previously (19, 26).
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